Background Recent work shows that hexosamine biosynthesis pathway (HBP) flux, not hyperglycemia itself, drives diabetic pathology through sustained O‑GlcNAcylation of signaling proteins [https://pmc.ncbi.nlm.nih.gov/articles/PMC3025273/][https://www.ahajournals.org/doi/10.1161/JAHA.119.014046]. Acute HBP activation, however, confers cardioprotection and reduces protein aggregation in neurodegeneration models [https://www.pnas.org/doi/10.1073/pnas.1205748109]. Chronic HBP activity in aging mouse hearts promotes glycosaminoglycan accumulation and extracellular matrix dysregulation [https://doi.org/10.1101/2023.11.17.567640]. The mechanistic switch from benefit to harm remains unclear.

Hypothesis We propose that chronic HBP flux increases O‑GlcNAcylation of lamin A/C at specific serine/threonine residues located in its tail domain. This modification weakens lamin‑chromatin interactions, leading to peripheral heterochromatin loosening, aberrant release of sequestered transcription factors, and a global shift toward a pro‑senescent chromatin state. In the short term, modest O‑GlcNAcylation of lamin A/C enhances nuclear flexibility and supports stress‑responsive gene expression, accounting for the observed acute cardioprotective effects. Persistent modification, however, drives chromatin instability, reactivation of transposable elements, and accumulation of DNA damage, which together exacerbate insulin resistance, cardiac hypertrophy, and proteostatic collapse in diabetic aging.

Mechanistic Rationale Lamin A/C serves as a scaffold for heterochromatin protein 1 (HP1) and histone H3K9me3 marks. O‑GlcNAcylation of lamin residues sterically hinders HP1 binding, as demonstrated for other nuclear proteins where O‑GlcNAc blocks protein‑protein interfaces. Loss of lamina‑tethered heterochromatin increases nuclear accessibility of NF‑κB and AP‑1 sites, promoting inflammatory transcription that sustains HBP flux via GFAT upregulation—a positive feedback loop. Simultaneously, chromatin destabilization impairs the nucleoplasmic sequestration of aggregation‑prone proteins, reducing the nucleus’s capacity to act as a protein quality‑control compartment, thereby shifting the burden to the cytosol where chronic O‑GlcNAcylation of cytosolic targets (e.g., Bad, AMPK) promotes insulin resistance and maladaptive hypertrophy.

Testable Predictions

1. In diabetic cardiomyocytes, chronic (48‑hr) glucosamine treatment will increase O‑GlcNAc signal on lamin A/C detectable by lamin‑specific immunoprecipitation followed by O‑GlcNAc blot, whereas acute (6‑hr) treatment will produce a transient, lower‑amplitude signal.
2. Loss‑of‑function of OGT specifically in cardiomyocytes will prevent lamin A/C O‑GlcNAcylation, preserve peripheral H3K9me3 levels, and protect against diabetes‑induced heterochromatin loss, as measured by lamin‑DamID or ATAC‑seq of nuclear lamina-associated domains.
3. Expressing a lamin A/C mutant lacking the predicted O‑GlcNAc sites (Ser→Ala) in diabetic mice will maintain nuclear heterochromatin integrity, reduce fibrosis, and improve systolic function despite elevated HBP flux.
4. Conversely, a phosphomimetic O‑GlcNAc‑mimetic lamin (Ser→Asp) will recapitulate heterochromatin loosening and exacerbate diabetic cardiomyopathy even in the presence of OGA overexpression.
5. Single‑cell multi‑omics of human diabetic heart biopsies will reveal a correlation between lamin A/C O‑GlcNAcylation (detected by CUT&Tag for O‑GlcNAc) and loss of lamina‑associated heterochromatin markers, independent of glucose concentration.

Potential Experiments

• Treat human iPSC‑derived cardiomyocytes with azaserine (GFAT inhibitor) or DON to block HBP flux, then assess lamin A/C O‑GlcNAcylation and heterochromatin marks.
• Use CRISPR‑base editing to introduce the lamin A/C O‑GlcNAc site mutations in mice; subject them to streptozotocin‑induced diabetes and monitor cardiac function via echocardiography over 6 months.
• Perform proximity‑labeling (BioID) of lamin A/C under acute vs chronic HBP activation to identify altered interaction partners (e.g., HP1, LAP2β).

Implications If validated, this model reframes the dual role of HBP flux as a rheostat of nuclear mechanics rather than merely a metabolic sensor. It suggests that therapeutic strategies aiming to modulate O‑GlcNAc cycling must consider lamin‑targeted specificity: transient, low‑level O‑GlcNAcylation may be beneficial, whereas sustained modification drives chromatin‑mediated aging pathology. Selective OGT inhibitors that spare lamin A/C or lamin‑specific OGA activators could uncouple the protective nutrient‑sensing arm from the detrimental heterochromatin‑destabilizing arm, offering a precise route for diabetic‑age interventions.